CANBRIDGE PHARM.DL-00001 Total Assets
CANBRIDGE PHARM.DL-00001 total assets. Based on the latest financial reports, CANBRIDGE PHARM.DL-00001 (MF1) holds total assets worth €165.39 Million EUR (≈ $193.36 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MF1 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of CANBRIDGE PHARM.DL-00001 (2021–2025)
Total assets of CANBRIDGE PHARM.DL-00001 from 2021 to 2025. This chart illustrates how CANBRIDGE PHARM.DL-00001's total assets have evolved over time, based on quarterly financial data. See MF1 live share price for real-time trading data and today's change.
CANBRIDGE PHARM.DL-00001 - Asset Composition Analysis
CANBRIDGE PHARM.DL-00001 Total Assets Breakdown (December 2025)
CANBRIDGE PHARM.DL-00001 total assets breakdown as of December 2025. CANBRIDGE PHARM.DL-00001's total assets of €165.39 Million consist of 66.6% current assets and 33.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 40.3% |
| Accounts Receivable | €15.12 Million | 9.1% |
| Inventory | €20.57 Million | 12.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €54.71 Million | 33.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how CANBRIDGE PHARM.DL-00001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of CANBRIDGE PHARM.DL-00001 to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CANBRIDGE PHARM.DL-00001's current assets represent 66.6% of total assets in 2025, a decrease from 91.0% in 2021.
- Cash Position: Cash and equivalents constituted 40.3% of total assets in 2025, down from 83.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 5.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 33.1% of total assets.
CANBRIDGE PHARM.DL-00001 Competitors by Total Assets
Key competitors of CANBRIDGE PHARM.DL-00001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
CANBRIDGE PHARM.DL-00001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.24 | 0.09 | 0.24 |
| Quick Ratio | 0.20 | 0.08 | 0.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-345.17 Million | €-437.26 Million | €-314.98 Million |
CANBRIDGE PHARM.DL-00001 - Advanced Valuation Insights
This section examines the relationship between CANBRIDGE PHARM.DL-00001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | 41.6% |
| Total Assets | €165.39 Million |
| Market Capitalization | $90.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values CANBRIDGE PHARM.DL-00001's assets below their book value (0.55x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CANBRIDGE PHARM.DL-00001's assets grew by 41.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CANBRIDGE PHARM.DL-00001 (2021–2025)
The table below shows the annual total assets of CANBRIDGE PHARM.DL-00001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €165.39 Million ≈ $193.36 Million |
+41.59% |
| 2024-12-31 | €116.81 Million ≈ $136.57 Million |
-70.45% |
| 2023-12-31 | €395.36 Million ≈ $462.22 Million |
-43.68% |
| 2022-12-31 | €702.04 Million ≈ $820.76 Million |
-21.34% |
| 2021-12-31 | €892.52 Million ≈ $1.04 Billion |
-- |
About CANBRIDGE PHARM.DL-00001
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatme… Read more